NEW YORK – Full-Life Technologies, a radiopharmaceutical-focused firm, on Thursday closed a $37 million Series A funding round led by Sequoia China.
Other investors participating in the round included Yunion Healthcare Ventures, Junson Capital, CD Capital, and Kunlun Capital.
The funding will be used to advance Full-Life's pipeline of targeted radiopharmaceuticals. The company has two preclinical candidates undergoing investigational new drug application (IND)-enabling studies. One targets fibroblast activation protein, or FAP, which is expressed in most epithelial cancers, including breast, lung, colorectal, and pancreatic tumors.
The second candidate in IND-enabling studies targets Claudin 18.2, which is overexpressed in many stomach and lung cancers. Full-Life also has a candidate targeting guanylyl cyclase C in earlier preclinical development and four undisclosed targets in the discovery phase.
Full-Life is also developing theranostic nuclide products that it will pair with each drug candidate to guide patient selection.
Full-Life, based in Shanghai, launched last year with $10 million in seed funding. The company expects that the Series A raise will further bolster its ability to move its pipeline products into the clinic.
"The funds will enable us to advance our lead radiopharmaceutical compounds into first-in-human studies next year and accelerate the development of our global radioisotope production and logistics capabilities," Full-Life CEO Lanny Sun said in a statement.